What is standard, first-line therapy for men with mHSPC today?

A presentation at the ongoing annual meeting of the European  Society of Medical Oncology (ESMO), in Madrid, Spain, has offered us data comparing abiraterone acetate + prednisone + ADT to docetaxel + ADT in the treatment of men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

Ipatasterib in the treatment of mCRPC: now in Phase III trial

Ipatasterib is a new type of drug that can be used to block the so-called PI3K/Akt signaling pathway, which is often highly activated in men with metastatic, castration-resistant prostate cancer (mCRPC). … REAF MORE…

Chaarting direction after stampeding along the relevant latitude

So about 3 years after the initial report of the results from the CHAARTED trial, 2 years after the initial report from the ADT + docetaxel arm of the STAMPEDE trial, and 3 months after the reports and publication of data from the LATITUDE trial and the ADT + abiraterone arm of the STAMPEDE trial, … READ MORE …

An update on ODM-201 in the treatment of advanced prostate cancer

A while back now (in late 2014) Bayer initiated Phase III trials of the investigational agent ODM-201 — now also known as daralutamide — in the treatment of advanced prostate cancer. … READ MORE …

New review article on mHSPC and mCRPC

Below you will find a link to a valuable new review article on ongoing changes in the opportunities for evaluation and management of men with both hormone-sensitive and castration-resistant, metastatic prostate cancer (mHSPC and mCRPC). … READ MORE …

Some “Best of ASCO” reports from UroToday

The UroToday web site has now posted a number of “Best of ASCO” reports that might be of interest to some of our readers. … READ MORE …

Should you be adding abiraterone acetate to your ADT? — Part II

So one of the benefits of being at the annual ASCO meeting is that you get to talk to lots of medical oncologists who specialize in treating prostate cancer — if you are patient and polite. … READ MORE …